Vai al contenuto principale
  • Pinatel Eva Maria, Francesca Orso, Elisa Penna, Daniela Cimino, Angela Rita Elia, Paola Circosta, Patrizia Dentelli, Maria Felice Brizzi, Paolo Provero, Daniela Taverna. miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One 2014 Jan 6; 9(1).
  • E. Penna, F. Orso and D. Taverna. miR-214 as a key hub that controls cancer networks: small player, many functions. Journal of Investigative Dermatology, 2015 Apr;135(4):960-969. doi: 10.1038/jid.2014.479. Epub 2014 Dec 11.
  • Benjamin G. Cuiffo, Antoine Campagne, George W. Bell, Antonio Lembo, Francesca Orso, Evan C. Lien, Manoj K. Bhasin, Monica Raimo, Summer E. Hanson, Andriy Marusyk, Dorraya El-Ashry, Peiman Hematti, Kornelia Polyak, Fatima Mechta-Grigoriou, Odette Mariani, Stefano Volinia, Anne Vincent-Salomon, Daniela Taverna, Antoine E. Karnoub. MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and Promote Breast Cancer MetastasisCell Stem Cell, published online: October 16, 2014, Dec 4;15(6):762-74. 
  • A Petrelli, R Carollo, M Cargnelutti, F Iovino, M Callari, D Cimino, M Todaro, LR Mangiapane, A Giammona, A Cordova, F Montemurro, D Taverna, MG Daidone, G Stassi, S Giordano. MiR-100 sensitizes basal-like Breast Cancer Stem Cells to hormonal therapy via cell differentiation. Oncotarget, Feb 10;6(4):2315-30.
  • Penna E, Orso F, Cimino D, Vercellino I, Grassi E, Quaglino E, Turco E, Taverna D. miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation. Cancer Res. 2013 May 10. [Epub ahead of print]
  • Orso F, Balzac F, Marino M, Lembo A, Retta SF and Taverna D. . miR-21 coordinates tumor growth and modulates KRIT1 levels. Biochem Biophys Res Commun. 2013 Aug 16;438(1):90-6. doi: 10.1016/j.bbrc.2013.07.031. Epub 2013 Jul 18.
  • Pincini A*, Tornillo G*, Orso F,  Sciortino M,  Bisaro B, Camacho Leal MP, Lembo A, Brizzi MF, Turco E, De Pittà C, Provero P,  Medico E, DefilippI P,  Taverna D§ & Cabodi S§. Identification of p130Cas/ErbB2 dependent invasive signatures in transformed mammary epithelial cells. Cell Cycle. 2013 Aug 1;12(15):2409-22. doi: 10.4161/cc.25415. Epub 2013 Jun 28. § corresponding authors.
  • Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S, Bruno G, Cimino D, Taverna D, Deregibus MC, Rastaldi MP, Perin PC, Gruden G. Urinary Exosomal MicroRNAs in Incipient Diabetic Nephropathy. PLoS One. 2013 Nov 4;8(11):e73798. Doi 10.1371/journal.pone.0073798.
  • Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, Conti L, Lanzardo S, Taverna D, Merighi I, Calogero RA, Cavallo F, Quaglino E. miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2. Am J Pathol. 2013 Jun;182(6):2058-70.
  •  Elsarraj HS, Hong Y, Valdez K, Carletti M, Salah SM, Raimo M, Taverna D, Prochasson P, Bharadwaj U, Tweardy DJ, Christenson LK, Behbod F. Novel role of microRNA146b in promoting mammary alveolar progenitor cell maintenance.J Cell Sci. 2013 Apr 9. [Epub ahead of print]
  • D. Cimino, C. De Pittà, F. Orso, M. Zampini, S. Casara, E. Penna, E. Quaglino, M. Forni, C. Damasco, E. Pinatel, R. Ponzone, C. Romualdi, C. Brisken, M. De Bortoli, N. Biglia, P. Provero, G. Lanfranchi, D. Taverna (2012). miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS and CSF1. THE FASEB JOURNAL, 2013 Mar;27(3):1223-35. doi: 10.1096/fj.12-214692. Epub 2012 Dec 11.
  • Bisaro B, Montani M, Konstantinidou G, Marchini C, Pietrella L, Iezzi M, Galie M, Orso F, Camporeale A, Colombo SM, Di Stefano P, Tornillo G, Camacho-Leal MD, Turco E, Taverna D, Cabodi S, Amici A, Defilippi P.p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. Breast Cancer Res. 2012 Oct 26;14(5):R137.
  • Osella-Abate S, Novelli M, Quaglino P, Orso F, Ubezio B, Tomasini C, Berardengo E, Bernengo MG, Taverna D.Expression of AP-2α, AP-2γ and ESDN in primary melanomas: Correlation with histopathological features and potential prognostic value. J Dermatol Sci. 2012 Dec;68(3):202-4. doi: 10.1016/j.jdermsci.2012.09.008. Epub 2012 Sep 18.
  • Gagliardi PA, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia. 2012 Aug;14(8):719-31.
  • Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, Gompel A. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012 Jan;131(1):49-63. Epub 2011 Feb 19.
  • Tombolan L, Orso F, Guzzardo V, Casara S, Zin A, Bonora M, Romualdi C, Giorgi C, Bisogno G, Alaggio R, Pinton P, De Pittà C, Taverna D, Rosolen A, Lanfranchi G. High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma. Am J Pathol. 2011 Nov;179(5):2611-24. doi: 10.1016/j.ajpath.2011.07.018. Epub 2011 Sep 13.
  • Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I, Taverna D. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011 May 18;30(10):1990-2007. Epub 2011 Apr 5.
  • Friard O, Re A, Taverna D, De Bortoli M and Corà M. CircuitsDB: a database of mixed microRNA / Transcription. BMC Bioinformatics, 2010, 11:435-445. 
  • Dentelli P, Rosso A, Orso F, Taverna D and Maria Brizzi MF. miR-222 controls neovascularization by regulating STAT5A expression. Arteriosclerosis, Thrombosis and Vascular Biology, 2010, 30:1562-1568 
  • Orso F, Corà D, Ubezio B, De Bortoli M, Provero P, M. Caselle and Taverna D. Analysis of the regulatatory regions of AP-2amodulated genes. BMC Genomics, 2010, 11: 355. 
  • Cabodi S. and Taverna D. Interfering with inflammation: a new strategy to block breast cancer self-renewal and progression? Breast Cancer Research, 2010, 12:305. 
  • Thewes V, Orso F,  Jäger R, Eckert D, Kirfel G, Garbe G, Taverna D and Schorle H. Interference with Activator Protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation- sensitivity in breast cancer cells. BMC Cancer, 2010, 10:192
  • Orso F, Jaeger R, Calogero RA, Schorle H, Sismondi P, De Bortoli M and Taverna D. AP-2ALPHA REGULATES MIGRATION OF GN-11 NEURONS VIA A SPECIFIC GENETIC PROGRAM INVOLVING THE AXL RECEPTOR TYROSINE KINASE. BMC Biology, 2009, 7:25.
  • Re A, Corà D, Taverna D and Caselle M. GENOME WIDE SURVEY OF MICRO RNA-TRANSCRIPTION FACTOR REGULATORY CIRCUITS IN HUMAN. Mol. BioSyst., 2009, 5: 854-867.
  • Dentelli P, Trombetta A, Togliatto G, Zeoli A, Rosso A, Uberti B, Orso F, Taverna D, Pegoraro L, Brizzi MF. FORMATION OF STAT5/PPAR{GAMMA} TRANSCRIPTIONAL COMPLEX MODULATES ANGIOGENIC CELL BIOAVAILABILITY IN DIABETES. Arterioscler Thromb Vasc Biol.,  2009 Jan;29(1):114-20.
  • Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, Russo G, Cicatiello L, Weisz A, Taverna D, Sismondi P, De Bortoli M. IDENTIFICATION OF NEW GENES ASSOCIATED WITH BREAST CANCER PROGRESSION BY GENE EXPRESSION ANALYSIS OF PREDEFINED SETS OF NEOPLASTIC TISSUES. Int J Cancer. 2008 Sep 15;123(6):1327-38.
  • Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, Giraudo E, Serini G, Sismondi P, De Bortoli M, Taverna D. AP-2ALPHA AND AP-2GAMMA REGULATE TUMOR PROGRESSION VIA SPECIFIC GENETIC PROGRAMS. FASEB J. 2008 Aug;22(8):2702-14. Epub 2008 Apr 28.
  • Orso F, Fassetta M, Penna E, Solero A, De Filippo K, Sismondi P, De Bortoli M, Taverna D. THE AP-2ALPHA TRANSCRIPTION FACTOR REGULATES TUMOR CELL MIGRATION AND APOPTOSIS. Adv Exp Med Biol. 2007;604:87-95.
  • Taverna D, Crowley D, Connolly M, Bronson RO and Richard Hynes. (2005). A DIRECT TEST OF POTENTIAL ROLES FOR BETA3 AND BETA5 INTEGRINS IN GROWTH AND METASTASIS OF MURINE MAMMARY CARCINOMAS. Cancer Res. Nov 15; 65(22):10324-9.
  • Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RO. (2004). INCREASED PRIMARY TUMOR GROWTH IN MICE NULL FOR BETA3- OR BETA3/BETA5-INTEGRINS OR SELECTINS. Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):763-8.
  • Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM.Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002 Jan;8(1):27-34.

Last update: 21/09/2018 23:32
Location: https://www.dmbhs.unito.it/robots.html
Non cliccare qui!